News digest – Angelina Jolie, clinical trial transparency, testicular cancer and more

The latest cancer news

The latest cancer news

  • We spotted several excellent comment pieces in response to Ms Jolie’s news. She’d “done something extraordinary”, according to Hadley Freeman in the Guardian, a sentiment broadly echoed by Lisa Markwell in the Independent, who has had breast cancer herself.
  • The Guardian’s data blog took a look at the bigger picture of breast cancer worldwide.
  • We also published this moving article about a personal experience of being told you have the BRCA1 gene.

Continue reading

Building an artificial tumour in the lab

Professor Fran Balkwill

Fran Balkwill plans to build the world’s first artificial tumour

In 2000, a team of archaeologists in the ancient Egyptian city of Thebes uncovered the mummified remains of a young woman called Tabaketenmut. The big toe of her right foot was missing. In its place was a wood and leather contraption tied to the limb with string, which researchers believe to be the earliest example of a prosthetic body part.

This rudimentary device – developed more than 2,000 years ago to help a woman walk – is often cited as one of the first and most primitive examples of bioengineering, the use of artificial components to replace damaged or absent parts of the body.

Today the term has a much broader meaning and includes disciplines such as materials science, biology, mathematics, engineering and computing. And we’ve come an incredibly long way since – thanks to primitive bioengineering – Tabaketenmut walked the earth.

Just last month, we heard the astonishing news that scientists have been able to grow a functioning kidney in the lab. And researchers in the US have developed a high-tech ‘lung on a chip’ to help them study infections and other diseases.

Now Cancer Research UK scientist Professor Fran Balkwill is looking to make a similarly monumental step forward in cancer biology by bioengineering the first ever three-dimensional artificial tumour.

She hopes the work will underpin the development of new treatments that attack the interactions between cancer cells and healthy tissues that unwittingly support them, known as the microenvironment.

Continue reading

News digest – tobacco disappointment, genetic ‘fine tuners’, vaccine cost drop, and more

The latest cancer news

The latest cancer news

  • Wednesday was a sad day for public health. The worrying rumours we’d heard last week – that the government had scrapped plans to introduce plain, standardised tobacco packaging in the Queen’s speech – turned out to be true. This BBC article has more info. We wrote about why this is a blow in the fight against cancer.
  • Our scientists found that genetic ‘fine tuners’ known as microRNAs control the body’s own attack against breast cancer. Read more in our press release
  • US scientists uncovered why breast cancer patients with dense breasts are often more likely to develop aggressive tumours that spread. This NewsWise article has more info.
  • Also across the pond, researchers at the Stanford University School of Medicine identified a group of proteins that are faulty in about one-fifth of all human cancers. Science Daily covered the story.
  • Pharmaceutical companies agreed a substantial discount on the cost of cervical cancer vaccines for the developing world. The New York Times and the Guardian have more detail.

And finally

  • We were dismayed this week by several headlines like this: “Sun’s blood pressure benefits may outdo cancer risks”. The study in question only looked at the blood pressure of 24 volunteers who sat beneath tanning lamps. It didn’t directly look at skin cancer risk and also hasn’t been published in a peer-reviewed journal yet. Overexposure to UV radiation from the sun or sunbeds is the main cause of skin cancer, so we advise everyone to enjoy the sun safely.

News digest – breast cancer rates, worrying tobacco rumours, genetic maps and more

man reading newspaper

It’s time for our round-up of the week’s headlines

  • In other breast cancer news, tamoxifen and similar oestrogen-blocking drugs have been found to reduce breast cancer rates by more than a third in women at high risk. Our press release and blog both have more detail. We also liked this Telegraph piece about tamoxifen.
  • Several papers (including the Guardian) covered research about a possible link between cosmetic breast implants and a greater chance of dying from breast cancer. The research does not suggest implants cause cancer, but they may cause a delay in diagnosis. As this excellent NHS Choices analysis says, larger studies are needed to understand this link.

Continue reading

News digest – radioactive bacteria, plain tobacco packs, gene patenting and more

The latest cancer news

Catch up on the latest cancer news

  • For those who don’t know why we want the Government to legislate for plain standardised tobacco packaging, read this excellent Lancet Oncology article.
  • We want to give children one less reason to start smoking but interestingly, our research this week showed that standardising cigarette packs also makes them less appealing to existing smokers (press release).
  • Some Welsh cancer patients aren’t starting their treatment within government target times. The BBC has more detail.
  • The Telegraph published an interesting article about using computers to choose cancer treatments. It’s not the stuff of science fiction, as doctors already use computer programmes to help identify the most suitable treatments for their patients.
  • In another sci-fi-like story, US scientists have used radioactive bacteria to treat mice with pancreatic cancer. It’s intriguing work but as this Nature article says, there are several crucial questions that need answering before this research could be harnessed for humans.
  • A small but interesting study we funded showed that women are often surprised that breast screening can lead to ‘overdiagnosis’ of cancer, but would rather go for screening than take the risk of missing a cancer that could be treated. Here’s our press release.
  • The ‘breast cancer’ drug, Herceptin, could be effective in around two per cent of lung cancers, according to preliminary research reported here.
  • An innovative drug development fund, provided in part by our commercial company Cancer Research Technology, backed its first major project this week. Here’s our press release, and we wrote in more detail about the science behind the promising compounds being developed – ‘MPS1 inhibitors’.
  • According to a new analysis, rising cancer rates are threatening to ‘overwhelm’ Latin American countries. The BBC has this take.
  • The Guardian wrote a fascinating piece about gene patenting and what they describe as “the last-ditch battle over who owns the rights to our DNA”.
  • And the New York Times had a great article about how whole genome DNA sequencing will one day become the norm across health care, and the current “arms race” between US institutions to invest in DNA sequencing technologies.

And finally

  • We recently described how a new blood test could track tumours as they grow and evolve in the body. Picking up this theme, our blogger Dr Kat Arney has looked into this exciting new area in more depth in an Opinion piece for Al Jazeera English. 

Innovative drug development fund backs first major project

Molecular machinery of a dividing cell. Image courtesy of Wikimedia Commons

MPS1 inhibitors block a molecule involved in cell division.

Last year we were extremely excited to launch an innovative fund to bring new cancer drugs to patients.

Today we’re pleased to reveal that the fund has given the green light to its first project, aimed at accelerating the development of a promising group of compounds called MPS1 inhibitors into effective new cancer drugs.

The £50 million fund has been developed to address the sobering reality that the process of turning promising investigational drugs into ‘real life’ treatments for cancer patients is very often unsuccessful. The fund, half of which is provided through our commercial company Cancer Research Technology (CRT), is central to our strategy to make sure that exciting drug discoveries don’t languish at the lab bench, but are given every chance to be transformed into future cancer cures.

Called the CRT Pioneer Fund, it’s being run by independent management firm Sixth Element Capital, who have spent the last few months selecting exciting drug discovery opportunities from around the country.

Read on to find out why work on MPS1 inhibitors by researchers at The Institute of Cancer Research, London, piqued their interest and led to the first grant from the Pioneer Fund.

Continue reading

News digest – misleading tobacco ads, new type of bowel cancer, platy fish and more

Newspapers

Read about cancer news from the past week

  • Lots of tobacco news this week. On Monday we learnt that smokefree legislation has been linked to a drop in emergency hospital admissions from asthma. Here’s our news story.
  • In parliament on Tuesday, the government confirmed that it’s taking a “careful look” at all the evidence coming out of the consultation on standardised packaging on tobacco products (news story). Let’s hope they make the right decision and give children one less reason to start smoking.
  • On Wednesday, we had a timely reminder of tobacco industry tactics. The Advertising Standards Agency ruled that a series of ads from Japan Tobacco International which made claims that cannot be substantiated had breached the UK advertising code. The Guardian has more info, and you can read our view of these tactics here.

Continue reading